Page last updated: 2024-11-04

vorinostat and Follicular Thyroid Carcinoma

vorinostat has been researched along with Follicular Thyroid Carcinoma in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

ExcerptRelevanceReference
"In both, thyroid cancer is driven by overactivation of PI3K-AKT signaling."1.43SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model. ( Cheng, SY; Kim, DW; Willingham, MC; Zhao, L; Zhu, X, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhu, X1
Kim, DW1
Zhao, L1
Willingham, MC1
Cheng, SY1

Other Studies

1 other study available for vorinostat and Follicular Thyroid Carcinoma

ArticleYear
SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.
    Endocrine-related cancer, 2016, Volume: 23, Issue:7

    Topics: Adenocarcinoma, Follicular; Animals; Carcinogenesis; Disease Models, Animal; Hydroxamic Acids; Mice,

2016